File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety evaluation of telbivudine

TitleSafety evaluation of telbivudine
Authors
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eds
Citation
Expert Opinion On Drug Safety, 2010, v. 9 n. 5, p. 821-829 How to Cite?
AbstractImportance of the field: Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects. Telbivudine is one of the more potent options available, with a 6.5- to 6.6-log copies/ml hepatitis B DNA reduction at 12 weeks in an early viral kinetic study, a potency comparable to entecavir. It is also one of the few drugs in the treatment of CHB under FDA pregnancy Category B. Areas covered in this review: The efficacy and safety profile of telbivudine in compensated and decompensated CHB patients compared to other agents are discussed. Viral resistance, characteristic adverse effects including elevation in creatine kinase and peripheral neuropathy in telbivudine treatment are reviewed. Infrequent but significant adverse effects of other nucleoside/nucleotide analogs are highlighted. What the reader will gain: Readers are provided the latest update on the clinical profile of long-term use of telbivudine. Take home message: Long-term telbivudine treatment offers effective viral suppression to CHB patients with certain baseline characteristics and on-treatment virologic response. Creatine kinase elevation is not a good predictor of muscle-related adverse effects with nucleoside/nucleotide analogs. But significant myopathy and neuropathy have been reported in a small number of patients receiving telbivudine. © 2010 Informa UK, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163331
ISSN
2015 Impact Factor: 2.896
2015 SCImago Journal Rankings: 1.029
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBut, DYKen_US
dc.contributor.authorYuen, MFen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:30:07Z-
dc.date.available2012-09-05T05:30:07Z-
dc.date.issued2010en_US
dc.identifier.citationExpert Opinion On Drug Safety, 2010, v. 9 n. 5, p. 821-829en_US
dc.identifier.issn1474-0338en_US
dc.identifier.urihttp://hdl.handle.net/10722/163331-
dc.description.abstractImportance of the field: Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects. Telbivudine is one of the more potent options available, with a 6.5- to 6.6-log copies/ml hepatitis B DNA reduction at 12 weeks in an early viral kinetic study, a potency comparable to entecavir. It is also one of the few drugs in the treatment of CHB under FDA pregnancy Category B. Areas covered in this review: The efficacy and safety profile of telbivudine in compensated and decompensated CHB patients compared to other agents are discussed. Viral resistance, characteristic adverse effects including elevation in creatine kinase and peripheral neuropathy in telbivudine treatment are reviewed. Infrequent but significant adverse effects of other nucleoside/nucleotide analogs are highlighted. What the reader will gain: Readers are provided the latest update on the clinical profile of long-term use of telbivudine. Take home message: Long-term telbivudine treatment offers effective viral suppression to CHB patients with certain baseline characteristics and on-treatment virologic response. Creatine kinase elevation is not a good predictor of muscle-related adverse effects with nucleoside/nucleotide analogs. But significant myopathy and neuropathy have been reported in a small number of patients receiving telbivudine. © 2010 Informa UK, Ltd.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/edsen_US
dc.relation.ispartofExpert Opinion on Drug Safetyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntiviral Agents - Administration & Dosage - Adverse Effects - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshBiological Markersen_US
dc.subject.meshCreatine Kinase - Blooden_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Resistance, Viral - Geneticsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B Virus - Drug Effects - Enzymology - Geneticsen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshIsoenzymes - Blooden_US
dc.subject.meshMaleen_US
dc.subject.meshMulticenter Studies As Topic - Statistics & Numerical Dataen_US
dc.subject.meshMuscular Diseases - Blood - Chemically Induceden_US
dc.subject.meshNucleosides - Administration & Dosage - Adverse Effects - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshPeripheral Nervous System Diseases - Chemically Induceden_US
dc.subject.meshPredictive Value Of Testsen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Complications, Infectious - Drug Therapyen_US
dc.subject.meshPyrimidinones - Administration & Dosage - Adverse Effects - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.titleSafety evaluation of telbivudineen_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/14740338.2010.507190en_US
dc.identifier.pmid20662545en_US
dc.identifier.scopuseid_2-s2.0-77955929197en_US
dc.identifier.hkuros181287-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955929197&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue5en_US
dc.identifier.spage821en_US
dc.identifier.epage829en_US
dc.identifier.isiWOS:000282077900012-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridBut, DYK=24343113400en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.citeulike7721316-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats